Skip to content

Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis

Randomised Controlled Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02630433
Enrollment
65
Registered
2015-12-15
Start date
2009-08-31
Completion date
2017-11-12
Last updated
2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis

Keywords

Biliary pancreatitis, Cholecystectomy

Brief summary

There are controversies optimal timing for cholecystectomy in patients with mild biliary pancreatitis. The safety of cholecystectomy performed during an episode of pancreatitis has been questioned. The aim of the present randomized controlled trial is to compare the outcome in terms of recurrent pancreatitis and gallstone-related events between index cholecystectomy, performed during the first admission for acute pancreatitis, and scheduled cholecystectomy, performed 4-6 weeks after discharge.

Detailed description

Background: There is still considerable debate regarding the optimal timing of cholecystectomy in mild biliary pancreatitis. It is widely accepted to wait until the patient's clinical condition allows performing cholecystectomy in severe biliary pancreatitis with systemic or local complications. On the other hand, the recommendations are not very clear when it comes to patients with mild biliary pancreatitis. The British Society of Gastroenterology and American Gastroenterological Association guidelines recommendation is to perform cholecystectomy within 2-to 4- week interval after the initial episode. However, the safety of cholecystectomy performed during an episode of pancreatitis is also controversial. In a systematic review the overall readmission rate was 18% after index cholecystectomy, 8% for recurrent biliary pancreatitis, 3 % for acute cholecystitis and 7 % for biliary colic. Methods The study is performed as a Randomised controlled trials with two parallel arms and a ratio of 1:1. Patients admitted with acute pancreatitis are checked for eligibility criteria for the study. Mild pancreatitis is defined as pancreatitis without local complications such as necrosis or organ failure. Patients who are eligible obtained oral and written information about the study and invited to be included. Patients who accept participation sign a consent form and are included. The included patients are randomized into index cholecystectomy (IC) or scheduled cholecystectomy (SC). Randomization is done with a sealed envelope system. The allocation sequence is created by an online random generator. There is no blocking. After randomization, the patient as well as the responsible are immediately informed about the allocation. The IC and SC are protocolled to be performed within 24-48 hours from randomization, and after 6 weeks from discharge respectively. Daily blood samples, pain and well-being scores are obtained during index admission until discharge, at 1-month follow-up for SC group and at the scheduled cholecystectomy. Quality of life is assessed with SF-36 prior to randomization and 4 weeks after inclusion. Pain is measured with the McGill Pain Questionnaire before randomization and daily until discharge of two days after inclusion. Sample size estimation If IC reduces the risk of gallstone- or treatment-related adverse events from 40% to 10%, a total sample of 32 patients in each group is required in order to reach a chance of 80% of detecting a significant difference at the p\<0.05 level. In order to compensate of drop-outs, a total sample of 70 is stipulated.

Interventions

PROCEDUREIndex cholecystectomy

Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.

PROCEDUREScheduled cholecystectomy

Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* S-Amylase \>3 microkat/L * One or more gallstones with diameter \< 2 cm * S-CRP \< 150 mg/L the first 24 hours

Exclusion criteria

* Multiple organ failure * Solitary gallstone with diameter \>2 cm * Concurrent cholangitis * Hospital stay exceeding 72 hours before screening for inclusion

Design outcomes

Primary

MeasureTime frameDescription
Recurrent acute pancreatitis6 weeksRelapse of acute pancreatitis in the scheduled cholecystectomy arm

Secondary

MeasureTime frameDescription
Complications related to the cholecystectomy30 daysComplications according to the Clavien-Dindo classification
Markers of inflammatory activity3 daysInflammatory response measured with CRP and interleukins
Health-related quality of life measured with SF-366 weeksHealth-related quality of life measured with SF-36 the day of inclusion and 6 weeks after inclusion
Cost-effectiveness6 weeksCosts from hospital stay, the surgical procedure and sick leave.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026